21 computational-fluid-dynamics Senior Scientist positions at Pfizer in United States
Sort by
Refine Your Search
-
dynamic group of discovery/development ADME project representatives within the Pharmacokinetics, Dynamics and Metabolism (PDM) Department at Pfizer Cambridge, Massachusetts. Working with multidisciplinary
-
Job Summary: The Senior Scientist Computational Biologist will be a key member of the Machine Learning and Computational Sciences Team, focusing on the analysis and interpretation of complex
-
with a background in hormone-driven cancers to join a dynamic and fast-paced discovery biology team. The successful candidate will join the Oncogene & Cancer Vulnerabilities group embedded within
-
experimentation through enhanced analytics, computer vision and other emerging technologies. Develop and implement synergistic digital tools for machine learning and self-optimization to enhance automation goals
-
term incentive program. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life's moments. Benefits offered include a 401(k) plan
-
partnerships with colleagues within Research Units and adjacent partner lines to influence strategy and decision-making relating to the incorporation of functional genomics' capabilities to address key program
-
office settings which would require varying degrees of sitting, standing, moving about the workspace, light lifting, working at a computer, and performing routine laboratory tests and procedures. Also
-
12.5% of the base salary and eligibility to participate in our share based long term incentive program. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives
-
Engineering, Biochemistry, Biology, Pharmacology, Chemistry, Computer Science, or a related field with 9+ years of relevant experience in developing laboratory solutions in the pharmaceutical industry
-
cross functional teams including computational biology group to integrate complex data sets including epigenomic and other 'omic' data in pre-clinical settings for target validation and advance mechanism